Antibody specifically binding to epitope in SEMA domain of c-Met

1. An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, wherein the epitope consists of SEQ ID NO: 3 or a portion of SEQ ID NO: 1 that includes SEQ ID NO: 3, wherein the antibody or antigen binding fragment thereof does not comprise the same complementarity determining regions (CDRs) as an antibody produced by hybridoma KCLRF-BP-00200.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody, bispecific antibody, multispecific antibody or antigen binding fragment selected from the group consisting of scFv, (scFv)2, Fab, Fab′, and F(ab′)2.

3. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof specifically binds human c-Met protein.

4. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is an antagonist of c-Met protein.

5. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is synthetic or recombinant.

6. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

7. A method of treating a cancer characterized by c-Met expression in a human subject, the method comprising administering to the human subject the antibody or antigen binding fragment of claim 1 , or a pharmaceutical composition comprising the antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable carrier, a diluent, or an excipient.

8. The method of claim 7 , wherein the cancer is lung cancer, gastrointestinal cancer, or glioblastoma.